INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
GlobeNewsWire
Published: Jul 14, 2026, 08:54 PM
Sentiment Analysis
Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN).
Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether AstraZeneca and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On July 9, 2026, AstraZeneca disclosed that the late-stage Phase-3 CARDIO-TTransform trial of Wainua, an amyloid cardiomyopathy treatment developed in collaboration with Ionis Pharmaceuticals, did not meet its primary endpoint.
On this news, AstraZeneca’s American Depositary Share (“ADS”) price fell $10.79 per ADS, or 5.7%, to close at $187.49 per ADS on July 9, 2026.
Source: GlobeNewsWire
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.